10-K: VitaSpring Biomedical Faces Going Concern Doubt

VitaSpring Biomedical Co., Ltd. filed its annual report, highlighting substantial doubt about its ability to continue as a going concern due to a lack of revenue and significant liabilities.

Summary

• VitaSpring Biomedical Co., Ltd. has filed its annual report for the fiscal year ended January 31, 2026.
• The company is in a development stage and has not generated revenue in the past two fiscal years.
• As of January 31, 2026, the company reported a cash balance of $2,084, total assets of $14,676, and total liabilities of $4,445,244, resulting in a stockholders' deficit of $4,430,568.
• The company's financial statements have been prepared with substantial doubt about its ability to continue as a going concern within the next twelve months.
• Operating expenses decreased to $385,411 in fiscal year 2026 from $679,914 in fiscal year 2025.
• Net loss for fiscal year 2026 was $415,368, an improvement from $774,922 in fiscal year 2025.
• The company relies on external funding and related-party support, with no committed financing arrangements.
• A material weakness in internal control over financial reporting was identified due to insufficient segregation of duties and lack of personnel with U.S. GAAP and SEC reporting expertise.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the explicit statement of substantial doubt about the company's ability to continue as a going concern, lack of revenue, and significant financial deficiencies.

Positives

• Net loss decreased by $359,554 to $415,368 for the year ended January 31, 2026, compared to the prior year.
• Operating expenses were reduced by $294,503 to $385,411 for the year ended January 31, 2026, compared to the prior year.
• A deferred payment agreement was entered into on May 18, 2026, deferring collection efforts for $2,411,000 in accounts payable to a related party for 24 months.
• The company's research and development team has received multiple honors, including Taiwan National Innovation Awards.
• The company has a new management team and strategic direction focused on regenerative medicine and functional wellness.

Negatives

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• The company has not generated revenue in fiscal years 2025 and 2026.
• As of January 31, 2026, the company has a working capital deficiency of $4,434,717.
• The company has an accumulated deficit of $5,696,871 as of January 31, 2026.
• The company has minimal cash reserves ($2,084 as of January 31, 2026) and insufficient liquidity to fund operations for the next twelve months without additional financing.
• Liabilities substantially exceed assets.
• A material weakness in internal control over financial reporting has been identified.
• The company has no committed financing arrangements.
• The company's common stock is thinly traded on the OTC Pink marketplace.
• The company has no full-time employees other than its sole executive officer and director.

Risks

• The company's ability to continue as a going concern is in doubt due to lack of revenue, insufficient liquidity, and substantial liabilities.
• Failure to secure additional capital could force the company to significantly curtail or cease operations.
• The company's liabilities substantially exceed its assets, potentially impairing its ability to obtain financing and satisfy uplisting requirements.
• The company's business model is speculative and subject to significant execution risk, including securing capital, obtaining regulatory approvals, and establishing manufacturing capabilities.
• If the company pursues regenerative medicine or biologic-based products, it will be subject to extensive and evolving regulatory requirements.
• The company does not currently hold any issued patents or registered trademarks, relying on trade secrets and proprietary know-how, which are difficult to protect.
• Significant obligations to related parties, including a former officer involved in criminal proceedings, pose a risk.
• The company's governance structure, with a single director and no independent committees, increases the risk of conflicts of interest.
• Former officers are involved in legal proceedings in Taiwan that could indirectly affect the company.
• A material weakness in internal control over financial reporting could lead to an inability to prevent or detect material misstatements.
• The company will require substantial additional capital, and future equity offerings may be highly dilutive.
• The company's net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code.
• The company may not satisfy the financial and governance requirements necessary to uplist to OTCQB or a national securities exchange.
• The company's common stock is thinly traded and may experience significant volatility and be subject to penny stock regulations.
• The company does not maintain a formal cybersecurity risk management framework, increasing vulnerability to breaches.
• Adverse economic conditions may affect the company's ability to raise capital.
• The company may become subject to securities class action litigation or stockholder derivative actions.

Future Outlook

The company anticipates needing substantial additional capital to execute its business strategy, fund operations, and pursue research and development initiatives. Future funding is expected to come from equity offerings, convertible securities, strategic partnerships, or related-party financing. There is no assurance that such financing will be available on acceptable terms. The company may need to delay or scale back operations if adequate funding is not secured.

Management Comments

• Management believes that internally reported testing has indicated materially higher exosome concentration levels compared with certain conventional MSC cultures; however, these findings have not been independently validated or reviewed by regulatory authorities.
• Management anticipates that X.msc-based projects will progress to limited hospital implementation within approximately five years, as part of our broader plan to integrate laboratory innovation into clinical application.
• Management concluded that substantial doubt exists regarding our ability to continue as a going concern within twelve months from the issuance of our financial statements.
• Management plans to continue seeking additional capital through equity financing, strategic partnerships, and related-party support in order to fund operating expenses and meet its obligations as they become due.
• Management assessed the effectiveness of our internal control over financial reporting as of January 31, 2026, and concluded that it was not effective due to a material weakness.

Industry Context

StockSavvy.ai notes that VitaSpring Biomedical operates in the rapidly growing regenerative medicine and functional wellness industry, which is projected to reach approximately $58 billion in 2026. Key trends include the growth of cell-based therapies, preventive and personalized medicine, evolving regulatory pathways, and the integration of biotechnology with aesthetics. However, the industry is highly fragmented and competitive, with many players having significantly greater resources.

Comparison to Industry Standards

• The regenerative medicine market was estimated at approximately $48 billion in 2025 and is projected to grow to approximately $58 billion in 2026, indicating a strong growth trend that VitaSpring aims to capitalize on.
• The company aims to establish advanced medical research and cell production centers meeting Good Tissue Practice (GTP) standards, which is an industry standard for cell therapy manufacturing.
• VitaSpring's focus on allogeneic mesenchymal stem cell (MSC) processing derived from maternal placenta aligns with emerging trends in cell-based therapies.
• The company's intention to align procedures with Good Manufacturing Practice (GMP) principles is a standard requirement for companies seeking to commercialize biomedical products.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently involved in any legal proceedings.
• Certain former officers are involved in civil and criminal proceedings in Taiwan relating to alleged unauthorized use of proprietary know-how and intellectual property. The company is not a named party to these proceedings.

Related Party Transactions

• As of January 31, 2026, the company owed $2,411,000 to a related-party vendor owned by a former officer.
• As of January 31, 2026, the company had $1,037,983 in advances from related parties, including from a former CEO and Chairman.
• On May 18, 2026, a deferred payment agreement was entered into with a related party for $2,411,000 in accounts payable, deferring collection efforts for 24 months.
• Operating expenses totaling $223,378 in FY2026 and $369,689 in FY2025 were paid on behalf of the company by related parties.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future capital raises, difficulty in trading shares due to low liquidity, and risk of losing entire investment due to going concern issues.
• Creditors: Potential inability to satisfy obligations if creditors demand repayment or decline to extend payment terms.
• Employees: As the company currently has only one executive officer, the impact on employees is minimal, but future hiring plans suggest growth potential.
• Suppliers: Potential for delayed payments given the company's financial condition and related-party payment deferral agreements.

Next Steps

• The company plans to explore and implement R&D programs once sufficient funding becomes available.
• Future R&D efforts are expected to emphasize scientific validation, process optimization, and regulatory readiness.
• The company intends to pursue intellectual property protection through patent and trademark filings.
• The company plans to implement data protection and cybersecurity measures as operations expand.
• The company intends to expand its organization by hiring key personnel in R&D, quality assurance, regulatory affairs, and business development.
• The company plans to establish programs that promote employee development, inclusion, and ethical conduct.
• The company intends to evaluate and enhance its internal control procedures and hire additional qualified personnel or engage external consultants to remediate the material weakness.
• The company intends to adopt a Code of Business Conduct in Q2 of 2026.
• The company intends to evaluate the formation of appropriate Board committees as operations grow.

Key Dates

Recommendation

The company's financial condition presents a severe going concern risk, with no revenue, substantial liabilities exceeding assets, and a material weakness in internal controls. The reliance on future financing and related-party support, coupled with the speculative nature of its development-stage business, makes it a high-risk investment. The lack of progress in commercialization and the significant financial challenges suggest a sell recommendation.

Keywords

VitaSpring Biomedical, 10-K, Annual Report, Biomedical, Regenerative Medicine, Stem Cells, Exosomes, Development Stage, Going Concern, Financial Statements, SEC Filing, Nevada, Biotechnology